Alzheimer’s Disease: Adult-Onset of Inborn Error of Methionine Metabolism

Abstract

The cause and treatment of Alzheimer’s Disease remains obscure. It could arise from adult onset of an inborn error of metabolism of the essential amino acid methionine expressed through an alternate biochemical pathway for methionine metabolism. This latter pathway generates homocysteine directly from methionine, accounting for the latter’s elevated vascular concentration in Alzheimer’s patients and those predisposed to this disease. Through this alternate pathway, synthesis of S-adenosylmethionine, an important component in memory retention, is precluded and accounts for the symptoms observed in patients. Suggestions for methods to increase brain concentrations of S-adenosylmethionine are presented. Alzheimer’s disease (AD) and related dementias currently affect approximately 5.4 million Americans (one out of eight older adults), and similar results are observed in other developed countries. It is the sixth leading cause of death in the U.S. and the only one in the top ten whose origin and effective treatment remain unknown [1]. The biggest risk factor for developing AD is age, and approximately one-third of those over 85 have some form of dementia. Since women live longer than men, they are at greater risk for developing AD. The financial costs in the U.S. of caring for individuals afflicted with AD and related dementia have been estimated to be $226 billion in 2015; and, without major improvement in early diagnosis and effective treatment, these costs are projected to rise to $1 trillion by 2050 [2]. Therefore, understanding the cause of AD has become a major health imperative. In an earlier publication, we proposed the possibility that AD might be related to an unexpected pathway in methionine metabolism [3]. The basis for such speculation stemmed from the observation that higher concentrations of homocysteine have been observed in the blood of patients with AD and those at risk for developing AD [4-8]. The source for such elevated homocysteine levels still remains obscure, but it could arise from the direct metabolism of methionine to homocysteine. It is also noteworthy that blood and brain concentrations of S-adenosylmethionine (SAM), an important biochemical for normal homeostasis, are severely depressed in AD patients [9]. The basis for this occurrence could be the unavailability of methionine to form SAM. From animal models, it has been determined that SAM is of critical importance in maintaining cognitive functions, especially memory retention [10]. All of these observations are consistent with and support the hypothesis of the operation of an alternate pathway in methionine metabolism. The basis for AD may be an adult-onset of an Inborn Error of Metabolism (IEM) of methionine. The term IEM was first proposed by Archibald Garrod and related to adult diseases [11]. However, the Figure 1: Diagram showing the pathway for the metabolism of methionine. This process enables maintenence of normal levels of SAM [22]. Citation: Soloway AH. Alzheimer’s Disease: Adult-Onset of Inborn Error of Methionine Metabolism. J Parkinsons Dis Alzheimer Dis. 2018;5(1): 3. J Parkinsons Dis Alzheimer Dis 5(1): 3 (2018) Page 02 ISSN: 2376-922X cause of Alzheimer’s disease would explain the observed elevation of homocysteine in such patients and the concomitant reduction in SAM’s concentration in the brain, a critical compound for memory, spatial retention, and other cognitive functions [21]. Both pathways are shown in Figures 1 and 2. However, it remains unclear how such altered biochemistry translates into AD. It has been postulated that a diet high in methionine could increase the risk of AD [23]. However, there is no evidence supporting this assumption. With married couples who consume essentially the same diet for years, one partner may develop AD while the second shows no evidence of any cognitive impairment. If diet were a factor, it is more likely to be one involving genetic metabolic differences. The Biochemical Cause of AD One of the primary characteristics of mammalian biochemistry is its ability to metabolize a diverse group of chemical entities, preventing their accumulation that could inhibit normal metabolism. This is demonstrated when novel structures that have never been encountered by the system are modified to facilitate their elimination through excretion. An alternate pathway for methionine metabolism might possibly prevent the unneeded accumulation of this essential amino acid. This pathway generates homocysteine directly from methionine and may explain why those at risk for AD have shown elevated concentrations of homocysteine in their vascular systems [3-6]. Additionally, this new pathway does not produce SAM, which might account for its significant reduction in the brains of AD patients and a concomitant reduction in memory retention [7]. The term metabolome applies to the small molecular metabolites that occur in mammalian systems [24]. These may be various hormones, other signaling compounds and those small molecules found in biological material. It is now viewed that an individual’s metabolism may be a harbinger of one’s susceptibility to various diseases. Though the cause of AD remains to be determined, knowledge from the disease’s metabolism has been used to try to develop a possible therapy. An Approach in the Development of AD Therapy Although drug treatments are being developed for AD patients, it will be necessary to determine the blood level of homocysteine that can be tolerated before treatment should begin and the level of SAM before which memory is irreversibly compromised. Knowing this information will be just as essential as knowing the glucose level in the diabetic patient before initiating treatment or the anticoagulant status of patients at risk for strokes when blood pressure is significantly elevated. At present, such information and methods of analysis may be unknown, but noninvasive methods must be developed for these essential biomarkers. Many of the possible treatment approaches have focused on immunizing the patient against the products derived from AD, such as beta amyloid plaques [25]. Verubecestat, a BACE1 inhibitor involves a related effort [26]. These approaches are analogous to attempts to treat infectious diseases by immunizing the patient against the disease’s products while not addressing the cause. The failure rate for AD drug therapy has been very significant [27]. It has been observed, contrary to expectations, that the removal of amyloid plaques did not improve cognitive function [28]. If the hypothesis proposed in this paper has some validity, it may be more appropriate to focus on increasing brain concentration of S-adenosylmethionine [29], which is commercially available in nutrition centers, since low brain concentration has been associated with irreversible changes in cognitive function. A major limitation in the use of SAM itself is its instability and the fact that it has not been optimized chemically to enhance its penetration of the blood-brain barrier (BBB) [30,31]. A compound’s lipophilicity has been related to its ability to penetrate the BBB and to concentrate in the CNS [31]. Such chemical changes in SAM may improve both its stability and potential use in brain concentration. Alternatively, one might consider the use of a liposome derived from SAM with the appropriate lipophilicity for CNS targeting. In addition to the chemical modification of SAM to enhance its lipophilicity and its CNS concentration, use of dietary factors known to increase brain concentration are appropriate and pertinent [3234]. These may meet the desired objective more rapidly. Nevertheless, understanding the various aspects involved with brain concentration of SAM remains an important and continuing biochemical objective. It has been shown that there is an immune basis for AD and that epigenomic changes in the hippocampus region of the CNS occur with Alzheimer’s neurodegeneration [35]. Understanding how an aging immune system influences the trajectory of this disease maybe essential in monitoring and modifying its normal course. Dedication This paper is dedicated to my wife, Barbara Soloway-who died of Alzheimer’s Disease, and to Heidi Pavoni, her caregiver at the Forum in Columbus, Ohio. References 1. Heerema E (2016) Statistics on Alzheimer’s disease: who gets it? Alzheimer’s Disease and Dementia. Figure 2: Alternate Pathway for Methionine Metabolism in Alzheimer’s patients. Here the metabolic process is interrupted and no SAM is produced. Citation: Soloway AH. Alzheimer’s Disease: Adult-Onset of Inborn Error of Methionine Metabolism. J Parkinsons Dis Alzheimer Dis. 2018;5(1): 3. J Parkinsons Dis Alzheimer Dis 5(1): 3 (2018) Page 03 ISSN: 2376-922X 2. Kennard C (2016) Statistics about the financial costs of alzheimer’s disease. Alzheimer’s disease and dementia. 3. Soloway AH, Soloway PD, Warner VD (2013) Possible chemical initiators of cognitive dysfunction in phenylketonuria, Parkinson’s disease and Alzheimer’s disease. Med Hypotheses 81: 690-694. 4. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, et al. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 346: 476-483. 5. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, et al. (2005) Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 82: 636-643. 6. Shea TB, Rogers E (2002) Homocysteine and dementia. N Engl J Med 346: 476-483. 7. Morris MS (2003) Homocysteine and Alzheimer’s disease. Lancet Neurol 2: 425-428. 8. Sachdev PS (2011) Alzheimer disease: homocysteine and alzheimer disease: an intervention study. Nature Rev Neurol 7: 9-10. 9. Morrison LD, Smith DD, Kish SJ (1996) Brain S-adenosylmethionine levels are severely decreased in Alzheimer’s disease. J Neurochem 67: 1328-1331. 10. Montgomery SE, Sepehry AA, Wangsgaard JD, Koenig JE (2014) The effect of S-Adenosylmethionine on cognitive performance in mice: an animal model met